|Bid||85.99 x 3000|
|Ask||86.00 x 100|
|Day's Range||85.91 - 86.56|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.48|
|Dividend & Yield||2.72 (3.17%)|
|1y Target Est||N/A|
The incoming chief executive of Novartis, Vas Narasimhan, has vowed to slash drug development costs, eyeing savings of up to 25 per cent on multibillion-dollar clinical trials as part of a "productivity ...
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.
In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis.